Valeant Pharmaceuticals North America LLC claims Mylan Pharmaceuticals Inc.'s proposal to make a generic version of a toenail infection treatment infringes its patent.
The company sued Mylan March 11 in the U.S. District Court for the Northern District of West Virginia in a bid to block copies of its Jublia drug until after Valeant’s U.S. Patent No. 10,105,444 expires in July 2030.
Valeant is suing several generic drugmakers in a bid to protect Jublia sales as demand for its dermatology prescription drugs decline.
The company sued generic drugmakers Teva Pharmaceuticals USA Inc., Amneal Pharmaceuticals Inc., and Acrux Ltd. last year ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.